Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2026
|
| Subjects: | |
| Online Access: | https://doi.org/10.24875/RECICE.M25000527 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Introduction and objectives: To compare the effects of drug-coated balloon (DCB) vs drug-eluting stent (DES) in patients presenting with de novo large vessel coronary artery disease (CAD). Methods: We conducted a systematic research of randomized controlled trials comparing DCB vs DES in patients with de novo large vessel CAD. Data were pooled by meta-analysis using a random-effects model. The prespecified primary endpoint was target lesion revascularization (TLR). Results: A total of 7 trials enrolling 2961 patients were included. The use of DCB vs DES was associated with a similar risk of TLR (OR, 1.21; 95%CI, 0.44-3.30; I2 = 48%), all-cause mortality (OR, 1.56; 95%CI, 0.94- 2.57; I2 = 0%), cardiac death (OR, 1.65; 95%CI, 0.90-3.05; I2=0%), myocardial infarction (OR, 0.97; 95%CI, 0.58-1.61; I2 = 0%), major adverse cardiovascular adverse (OR, 1.19; 95%CI, 0.74-1.90; I2 = 13.5%) and late lumen loss (standardized mean difference [SMD], -0.35; 95%CI, -0.74 to 0.04; I2 = 81.4%). However, the DCB was associated with a higher risk of target vessel revascularization (OR, 2.47; 95%CI, 1.52-4.03; I2 = 0%) and smaller minimal lumen diameter during late follow-up (SMD, -0.36; 95%CI, -0.56 to -0.15; I2 = 34.5%). Nevertheless, prediction intervals included the value of no difference for both outcomes. Conclusions: In patients with de novo large vessel CAD the use of DCB vs DES is associated with a similar risk of TLR. However, the DES achieves better late angiographic results. © 2025 Sociedad Española de Cardiología. Published by Permanyer Publications. This is an open access journal under the CC BY-NC-ND 4.0 license.